170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Annual Report to Security Holders
Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Provides Business Update and Reports First Quarter 2026 Financial Results
Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
Other Events
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload